NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions

Abstract

• Six daily 1 h topical applications of 2 mg/ml NVN1000, a NO-releasing polymer, abrogated HPV-18 progeny virus production. • NVN1000 inhibits terminal squamous differentiation of both infected and uninfected PHK raft cultures. • NVN1000 reduces HPV-18 E6 and E7 proteins and activities. • NVN1000 impairs S-phase progression and induces DNA damage in infected cultures. • NVN1000 is a promising candidate for sustained inhibition of HPV DNA replication and progeny virus production.